Nepal | August 13, 2020

AstraZeneca tops estimates as coronavirus vaccine hopes persist

Reuters
Share Now:
  • Q2 profit and sales beat on portfolio strength
  • Reiterates 2020 guidance for what has been a strong year
  • Optimism around AZ/Oxford coronavirus vaccine high
  • Shares rise as much as 3% in morning trade

Britain’s AstraZeneca bettered second-quarter sales and profit estimates on Thursday, thanks to strong sales during the lockdowns from the drugmaker’s diverse product line-up, which now includes a front-running coronavirus vaccine candidate.

Optimism over its COVID-19 vaccine has fuelled what was already a strong year for the company as it also stuck by its 2020 outlook. AstraZeneca has gained from changes wrought by Chief Executive Pascal Soriot’s focus on products and bets on newer medicines.

The company reiterated that it was on track with late-stage trials for its coronavirus vaccine, which could be rolled out by the year-end.

Shares of London’s most valuable listed company on Thursday rose 3% at 88.6 pounds after product sales of $6.05 billion in the three months ended June 30 surpassed analysts’ consensus of $6.01 billion. The figure excludes payments from tie-ups.

Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca remains on track for a third consecutive year of growth.

AstraZeneca has had a busy few months: it took on development of the COVID-19 shot from Oxford University, got billions in government funding, signed several supply deals, and was even the subject of a mega-merger speculation – all while marching on with its core business.

Among drugs with better-than-expected revenues, sales of respiratory drug Symbicort rose 12% to $653 million, about $90 million above consensus, while revenue from cancer drug Lynparza jumped 62% to $554 million.

There are no approved vaccines for the illness caused by the novel coronavirus, but AstraZeneca’s shot is widely considered the leading candidate after results from early-stage human trials showed it was safe and produced an immune response.

Core earnings of 96 cents per share beat analysts’ expectation of 93 cents. Total revenue rose 11%.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Coronavirus vaccine: Russia ahead on track, who is next?

KATHMANDU: Over 150 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, of which 28 are in human clinical trials, according to the World Health Organization. Meanwhile, Russia has become the first country in the world to grant regulatory approval to a COVID-19 Read More...

Nepal COVID-19 Update: 484 new cases, 64 recoveries, eight deaths reported Wednesday

KATHMANDU: Nepal’s Health Ministry, in its regular press briefing, shared the latest updates on coronavirus contagion from across the country, and government’s response to the health crisis. As of today, 473,179 tests through Polymerase Chain Reaction (PCR) method have been carried out wh Read More...

Nepal sees highest Covid-19 death toll in a single day; eight deaths reported Wednesday

KATHMANDU: Nepal has logged eight more Covid-19 related fatalities in the last 24 hours. This is the highest single day death-toll from the coronavirus infection recorded so far. Spokesperson at Ministry of Health and Population, Dr Jageshwar Gautam, informed public about the eight cases of fatal Read More...

Worldwide coronavirus cases cross 20.41 million, death toll over 742,000

At least 20,414,289 people have been reported to be infected by the novel coronavirus globally and 742,207 people have died, a Reuters tally showed.  Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.  Read More...

Pandemic and State: How is state accountable?

COVID-19 Global Lens The COVID-19 pandemic presents the world with a huge challenge: everyone and every area is affected, and the response has to be both quick and consorted. This pandemic may be primarily a health crisis for some states, but COVID-19 is also an education crisis, an employment an Read More...

Kathmandu valley's coronavirus cases hit another record; 138 new infections reported today

KATHMANDU: Kathmandu valley, yet again, recorded the highest single-day Covid-19 cases on Wednesday with 109 new cases in Kathmandu district, 21 in Lalitpur, and eight in Bhaktapur. A total of 138 new infections were reported today from inside the valley. With today’s additions, active case Read More...

Dhading district

One week prohibitory order issued in Dhading to contain COVID-19 spread

DHADING: A prohibitory order has been decreed in Dhading's headquarters Dhadingbesi and its peripheral areas with the increase in COVID-19 transmission, since Wednesday. In an attempt to curb further potential spread of the highly contagious infection, the District Administration Office took a de Read More...

Bollywood actor Sanjay Dutt diagnosed with lung cancer

KATHMANDU: Bollywood actor Sanjay Dutt, who was rushed to hospital in Mumbai after complaining of chest discomfort and breathlessness, has been diagnosed with lung cancer. The news was confirmed by Bollywood's trade analyst and film industry insider Komal Nahta on August 11 night, according to I Read More...